SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending due to its robust community's focus on long-term conviction, patience, and a positive cultural ethos, frequently comparing itself to Bitcoin with a unique 'higher' vision. The community highlights its sustained stability on the Solana blockchain and actively promotes its 'Green Wave' and 'Free the Plant' narrative, connecting to the broader cannabis movement and hemp's potential.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending due to recent pipeline expansion with the acquisition of VLX-1005 and ongoing advancements for its lead candidate, Tecarfarin, including a collaboration with Abbott for its pivotal Phase 3 trial. The community is sharply divided, with some investors highlighting Tecarfarin's market potential as a warfarin alternative and the stock's low float for significant upside, while others voice concerns over dilutive financing, cash burn, and allegations of widespread bot promotion.

The Livepeer project aims to deliver a live video streaming network protocol that is fully decentralized, highly scalable, crypto token incentivized, and results in a solution which can serve as the live media layer in the decentralized development (web3) stack. In addition, Livepeer is meant to provide an economically efficient alternative to centralized broadcasting solutions for any existing broadcaster. In this document we describe the Livepeer Protocol - a delegated stake based protocol for incentivizing participants in a live video broadcast network in a game-theoretically secure way. We present solutions for the scalable verification of decentralized work, as well as the prevention of useless work in an attempt to game the token allocations in an inflationary system.  The Livepeer Token (LPT) is the protocol token of the Livepeer network. But it is not the medium of exchange token. Broadcasters use Ethereum's Ether (ETH) to broadcast video on the network. Nodes who contribute processing and bandwidth earn ETH in the form of fees from broadcasters. LPT is a staking token that participants who want to perform work on the network stake in order to coordinate how work gets distributed on the network, and to provide security that the work will get done honestly and correctly. LPT has the following purposes:  It serves as a bonding mechanism in a delegated proof of stake system, in which stake is delegated towards transcoders (or validators) who participate in the protocol to transcode video and validate work. The token, and potential slashing that occurs due to protocol violation, is necessary in order to secure the network against a number of attacks. More below. It routes work through the network in proportion to the amount of staked and delegated token, essentially serving as a coordination mechanism.  It is a unit of account that is specific to the Livepeer ecosystem, which forms the basis of a SectorCoin concept, applicable to additional functionality to be introduced in the future. Services such as DVR, closed captioning, ad insertion/monetization, and analytics can all plug into the Livepeer ecosystem and potentially make use of the security provided by staking LPT.  An initial allocation of Livepeer Token will be distributed so that stakeholders can fulfill various roles in, and use the network, and then additional token will be issued according to algorithmically programmed issuance over time.  Following the conventions of Ethereum and many popular ERC20 tokens, LPT will be divisible by 10 ^ 18, with larger denominations such as the LPT itself intended to be used for user level transactions such as staking, and smaller denominations intended to be used for protocol accounting.

Livepeer Token

Livepeer (LPT) is trending due to recent news regarding its integration with OpenAI's SORA for decentralized AI video processing, positioning it as a significant play in the burgeoning AI sector. The community is actively discussing this development, anticipating substantial price appreciation and the token's utility in making generative AI video more accessible. Additionally, ongoing high staking yields continue to draw investor interest, contributing to the buzz around LPT.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. (BNAI) is experiencing an explosive short squeeze, largely attributed to its low float and an AI-related deal. The community is actively comparing its parabolic surge to past runners like SMX, with many celebrating the squeeze and debating the sustainability of its extreme volatility and upward momentum.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian (TEAM) is a trending topic following strong Q1 earnings, which highlighted robust cloud growth and a significant share buyback, yet the stock has seen a notable decline. This divergence sparks intense community debate, with many viewing its deeply oversold state as an "unreal opportunity" against a backdrop of broader software sector weakness. Investors are evaluating the company's sticky products and strategic AI integrations amidst ongoing discussions about AI's impact on SaaS.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health (HROW) is trending as its VEVYE dry eye treatment gains significant market traction following a major PBM's decision to make it a preferred product, replacing a key competitor. The community is buzzing with optimism about VEVYE's accelerating sales momentum and eagerly anticipates upcoming product launches, fueling speculation around a potential short squeeze and the stock's long-term value in the ophthalmic sector.

ETHZilla Corp. is a technology company in the decentralized finance (DeFi) industry, which intends to connect financial institutions, businesses, and organizations worldwide by enabling secure, accessible blockchain transactions through Ethereum Network protocol implementations. It continues to maintain the deployment and development of its biotech and gaming operations. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZilla Corporation is actively trending following corporate moves to cancel executive stock awards and redeem convertible debt, actions that are generating buzz about a tighter share float and reduced overhang. While many anticipate a short squeeze and value appreciation tied to its Ethereum holdings and new real-world asset tokenization strategy, a significant portion of the community expresses concern over management's past decisions and potential dilution, leading to a polarized outlook on the stock's direction.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is trending due to its announced record preliminary revenue and promising 2026 guidance, alongside the significant milestone of its Eversense 365 long-term CGM integrating with the twiist automated insulin delivery system. The community is actively discussing this breakthrough integration, which many view as a game-changer for its superior technology and improved market positioning, even as some express frustration with management's communication and slow commercialization pace. This puts the spotlight on SENS amidst broader competition and ongoing speculation about future partnerships.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is heavily discussed as investors eagerly await the imminent release of 3-year data from its pivotal EMBARK study for ELEVIDYS, with many anticipating positive outcomes following the company's proactive announcement. Community sentiment points to significant short interest and a perceived undervaluation, fueling speculation of a notable stock movement. This key data readout is seen as a critical inflection point for its leading gene therapy and its broader pipeline in rare disease treatment.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi is actively reshaping its portfolio, with recent notable acquisitions of Dynavax, Blueprint Medicines, and Vigil Neuroscience driving significant community discussion and speculation around further potential takeovers of companies like Ocular Therapeutix. This strategic expansion aims to bolster its immunology, rare disease, and vaccine pipelines, leveraging established successes like Dupixent while navigating mixed clinical trial results for other key experimental drugs. The aggressive M&A activity highlights Sanofi's commitment to strengthening its market position amidst a dynamic pharmaceutical landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stifel Nicolaus Has Lowered Expectations for Manhattan Associates (NASDAQ:MANH) Stock Price

Stifel Nicolaus cut their price target on shares of Manhattan Associates from $240.00 to $225.00 and set a "buy" rating for the company in a research note on Friday...

Unveiling Manhattan Associates (MANH) Q4 Outlook: Wall Street Estimates for Key Metrics

Evaluate the expected performance of Manhattan Associates (MANH) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Massachusetts Financial Services Co. MA Acquires 312,858 Shares of Manhattan Associates, Inc. $MANH

Massachusetts Financial Services Co. MA grew its holdings in shares of Manhattan Associates, Inc. (NASDAQ:MANH - Free Report) by 86.1% in the 3rd quarter, according to the company in its most recent...

Manhattan Associates (MANH) to Release Earnings on Tuesday

Manhattan Associates (NASDAQ:MANH) will be releasing its Q4 2025 earnings after the market closes on Tuesday, January 27. (View Earnings Report at...

Stephens Investment Management Group LLC Has $89.05 Million Position in Manhattan Associates, Inc. $MANH

Stephens Investment Management Group LLC decreased its position in Manhattan Associates, Inc. (NASDAQ:MANH - Free Report) by 5.1% in the 3rd quarter, according to the company in its most recent 13F...

Manhattan Associates, Inc. $MANH is Pembroke Management LTD's 10th Largest Position

Pembroke Management LTD increased its stake in shares of Manhattan Associates, Inc. (NASDAQ:MANH - Free Report) by 32.8% in the 3rd quarter, according to the company in its most recent filing with...

Manhattan Associates, Inc. (NASDAQ:MANH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Manhattan Associates, Inc. (NASDAQ:MANH - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen analysts that are presently covering the stock, Marketbeat...

Manhattan Associates, Inc. $MANH Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB cut its stake in Manhattan Associates, Inc. (NASDAQ:MANH - Free Report) by 15.0% during the 3rd quarter, according to its most recent Form 13F filing with the...

What 10 Analyst Ratings Have To Say About Manhattan Associates

Manhattan Associates Announces Appointment of Katie Foote as Chief Marketing Officer

Manhattan Associates Inc. (NASDAQ: MANH) today announced the appointment of Katie Foote as its Senior Vice President and Chief Marketing Officer. A seasoned executive, she brings extensive experience...

Manhattan Associates, Inc. engages in the business of developing, selling, deploying, servicing, and maintaining software solutions designed to manage supply chains, inventory, and omnichannel operations for retailers, wholesalers, manufacturers, logistics providers, and other organizations. It operates through the following geographical segments: North and Latin America, Europe, Middle East, and Africa, and Asia Pacific. The company was founded by Deepak Raghavan in October 1990 and is headquartered in Atlanta, GA.

Manhattan Associates, Inc.

$MSFT

$AAPL

$TSLA

$META

Earnings season is heating up, and several major companies report next week, including Microsoft, Apple, Tesla, and Meta. Which are you most excited for?

Which earnings report are you most excited for next week? 
 
Drop a comment for others.

Current Price	$174.02
Prev Close	$170.20
Open	$171.06
Dividend Yield	0.00%
50-Day Moving Average	$173.95
Beta	1.23
Avg. Volume	518,756.95
PE Ratio	49.43

52-Week High	$299.27
52-Week Low	$140.81
Market Capitalization	$10B
EPS (Annual)	$3.51
Price to Book	33.91
Revenue Per Employee	$222,249.89
Enterprise Value/EBITDA	N/A

MANH
Manhattan Associates, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MANH News

MANHManhattan Associates, Inc.